Dealing with bone marrow biopsies in the staging of classical Hodgkin lymphoma: an old issue revisited in the F-18-fluorodeoxyglucose-positron emission tomography era

Imagem de Miniatura
Arquivos
art_GONCALVES_Dealing_with_bone_marrow_biopsies_in_the_staging_2015.PDF (734.24 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2015
Editora
TAYLOR & FRANCIS LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
PAULA, Henrique Moura de
CERCI, Juliano J.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
LEUKEMIA & LYMPHOMA, v.56, n.10, p.2883-2888, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Bone marrow biopsy is recommended for staging of classical Hodgkin lymphoma. The aim of this study was to compare bone marrow evaluation by histology with that obtained by F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET). One hundred and three cases of Classical Hodgkin Lymphoma were reviewed. All patients were submitted to FDG-PET evaluation. Bone marrow biopsy results were compared with clinical data and FDG-PET results. Ninety-one cases had available bone marrow biopsies. Overall, there were 16 positive and one suspect case. In five cases, the FDG-PET scan was positive and biopsy was negative: 1/5 was found to correspond to a bone fracture, 3/5 showed marked reactive bone marrow changes and in 1/5 no explanation for the discrepancy was found. FDG-PET showed high sensitivity, supporting the idea that when it is negative, biopsy could be avoided. Care should be taken in patients with a positive FDG-PET, where confirmation by bone marrow biopsy should be recommended.
Palavras-chave
Lymphoma and Hodgkin disease, morphology, prognostication
URI
https://observatorio.fm.usp.br/handle/OPI/12784
Referências
  1. Kremer M, 2005, VIRCHOWS ARCH, V447, P920, DOI 10.1007/s00428-005-0070-8
  2. Hines-Thomas MR, 2010, HAEMATOL-HEMATOL J, V95, P1691, DOI 10.3324/haematol.2010.025072
  3. URBA WJ, 1992, NEW ENGL J MED, V326, P678, DOI 10.1056/NEJM199203053261006
  4. Arber DA, 2005, AM J SURG PATHOL, V29, P1549, DOI 10.1097/01.pas.0000182405.65041.8b
  5. Hamilton R, 2014, LEUKEMIA LYMPHOMA, V55, P1049, DOI 10.3109/10428194.2013.821201
  6. Howell SJ, 2002, BRIT J HAEMATOL, V119, P408, DOI 10.1046/j.1365-2141.2002.03842.x
  7. Franco V, 2004, EUR J HAEMATOL, V73, P149, DOI 10.1111/j.1600-0609.2004.00292.x
  8. TEVELDE J, 1978, HISTOPATHOLOGY, V2, P31
  9. Moulin-Romsee G, 2010, EUR J NUCL MED MOL I, V37, P1095, DOI 10.1007/s00259-009-1377-5
  10. Salaun PY, 2009, EUR J NUCL MED MOL I, V36, P1813, DOI 10.1007/s00259-009-1183-0
  11. Cerci JJ, 2011, CL LYMPH MYELOM LEUK, V11, P314, DOI 10.1016/j.clml.2011.06.006
  12. CARBONE PP, 1971, CANCER RES, V31, P1860
  13. El-Galaly TC, 2014, LEUKEMIA LYMPHOMA, V55, P2349, DOI 10.3109/10428194.2013.875169
  14. LISTER TA, 1989, J CLIN ONCOL, V7, P1630
  15. MUNKER R, 1995, J CLIN ONCOL, V13, P403
  16. Hutchings M, 2006, HAEMATOL-HEMATOL J, V91, P482
  17. Mahoney DH, 1998, MED PEDIATR ONCOL, V30, P175, DOI 10.1002/(SICI)1096-911X(199803)30:3<175::AID-MPO9>3.3.CO;2-3
  18. Cerci JJ, 2009, CLINICS, V64, P491, DOI 10.1590/S1807-59322009000600002
  19. PROCTOR SJ, 1992, LEUKEMIA LYMPHOMA, V7, P17, DOI 10.3109/10428199209061558
  20. Cortes-Romera M, 2014, CLIN NUCL MED, V39, pE46, DOI 10.1097/RLU.0b013e31828e9504
  21. El-Galaly, 2012, J CLIN ONCOL, V30, P4508
  22. Ponzoni M, 2002, MODERN PATHOL, V15, P1273, DOI 10.1097/01.MP.0000037311.56159.13
  23. Roppe R., 2012, NCCN CLIN PRACTICE G
  24. Simpson CD, 2010, BRIT J HAEMATOL, V141, P820
  25. Swerdlow SH, 2008, WHO CLASSIFICATION T, P321

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - ODS/03